Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populations
Mayya Sedova, Lukasz Jaroszewski, Mallika Iyer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11

Showing 11 citing articles:

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 263-266
Open Access | Times Cited: 27
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 13
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 12
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Nature (2025)
Open Access | Times Cited: 1
CMPK2 is a host restriction factor that inhibits infection of multiple coronaviruses in a cell-intrinsic manner
Mingjun Zhu, Jiahuang Lv, Wei Wang, et al.
PLoS Biology (2023) Vol. 21, Iss. 3, pp. e3002039-e3002039
Open Access | Times Cited: 16
Resistance‐associated mutations to the anti‐SARS‐CoV‐2 agent nirmatrelvir: Selection not induction
Philippe Colson, Jérémy Delerce, Pierre Pontarotti, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 4
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Marnix Van Loock, Ellen Van Damme, Pravien Abeywickrema, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Modeling Mutation-Driven Emergence of Drug-Resistance: A Case Study of SARS-CoV-2
Congjie Shi, Thomas N. Vilches, Ao Li, et al.
Fields Institute communications (2023), pp. 161-174
Closed Access
Evaluating the Utility of EZC Pak, a 5-Day Combination Echinacea-Zinc-Vitamin C Dose Pack with or without Vitamin D, in the Management of Outpatient Upper Respiratory Infections
Aditya Radhakrishnan, Stephanie Spencer, Naveena Yanamala, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top